{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:09:27Z","timestamp":1774645767950,"version":"3.50.1"},"reference-count":36,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fondi di Ateneo"},{"DOI":"10.13039\/501100007514","name":"University of Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Human cytochrome P450 24 subfamily A member 1 (CYP24A1) loss-of-function mutations result in impaired activity of the 24-hydroxylase involved in vitamin D catabolism, thus inducing a vitamin D-dependent hypercalcemia. Homozygotes often present an overt clinical phenotype named idiopathic infantile hypercalcemia (IIH), whereas it is debated whether heterozygotes display an abnormal phenotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the clinical and biochemical features of heterozygous carriers of CYP24A1 variant and healthy wild-type controls sharing the same genetic and environmental exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A large family harboring the nonsense c.667A&amp;gt;T, p.Arg223* pathogenic variant in the CYP24A1 gene was evaluated. All subjects underwent clinical and biochemical evaluation and complete analysis of vitamin D metabolites using mass spectroscopy including 1,24,25(OH)3D3. Subjects were divided into 2 groups according to their genotype: heterozygotes and wild-type for the CYP24A1 variant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proband, a 40-year-old man, homozygous for p.Arg223* pathogenic variant, had a history of mild hypercalcemia with a seasonal trend, recurrent nephrolithiasis, and no episodes of acute hypercalcemia. He showed the highest serum levels of fibroblast growth factor 23, the highest 25(OH)D3\/24,25(OH)2D3 ratio and undetectable levels of 1,24,25(OH)3D3, which represent indicators of a loss-of-function CYP24A1. Compared with the wild-types, heterozygotes had higher serum calcium and 25(OH)D3 concentrations (P = .017 and P = .025, respectively), without any difference in the other biochemical parameters and in the rate of nephrolithiasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Heterozygotes exhibit a biochemical phenotype different from that of wild-type subjects. In clinical practice, these individuals might require surveillance because of the potential risk of developing hypercalcemia and related clinical manifestations if exposed to triggering factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa876","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T16:26:47Z","timestamp":1606667207000},"page":"708-717","source":"Crossref","is-referenced-by-count":19,"title":["Do the Heterozygous Carriers of a <i>CYP24A1<\/i> Mutation Display a Different Biochemical Phenotype Than Wild Types?"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-6325","authenticated-orcid":false,"given":"Alessandro","family":"Brancatella","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-3561","authenticated-orcid":false,"given":"Daniele","family":"Cappellani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Borsari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Piaggi","sequence":"additional","affiliation":[{"name":"Department of Information Engineering, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Baldinotti","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Genetics, University Hospital of Pisa, Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Adelaide","family":"Caligo","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Genetics, University Hospital of Pisa, Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenville","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-8588","authenticated-orcid":false,"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-9547","authenticated-orcid":false,"given":"Filomena","family":"Cetani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2020,11,29]]},"reference":[{"issue":"5","key":"2021122117330007300_CIT0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJMoa1103864","article-title":"Mutations in CYP24A1 and idiopathic infantile hypercalcemia","volume":"365","author":"Schlingmann","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122117330007300_CIT0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.abb.2011.11.003","article-title":"25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D","volume":"523","author":"Jones","year":"2012","journal-title":"Arch Biochem Biophys."},{"issue":"1","key":"2021122117330007300_CIT0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1194\/jlr.R031534","article-title":"Cytochrome P450-mediated metabolism of vitamin D","volume":"55","author":"Jones","year":"2014","journal-title":"J Lipid Res."},{"issue":"4","key":"2021122117330007300_CIT0004","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ecl.2017.07.011","article-title":"Genetic diseases of vitamin D metabolizing enzymes","volume":"46","author":"Jones","year":"2017","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2021122117330007300_CIT0005","first-page":"4982621","article-title":"Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1 gene: a case report and review of the literature","volume":"2019","author":"Cappellani","year":"2019","journal-title":"Case Rep Endocrinol."},{"issue":"1","key":"2021122117330007300_CIT0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00431-012-1818-1","article-title":"Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene","volume":"172","author":"Fencl","year":"2013","journal-title":"Eur J Pediatr."},{"key":"2021122117330007300_CIT0007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2015.06.018","article-title":"Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study","volume":"81","author":"Cools","year":"2015","journal-title":"Bone."},{"issue":"5","key":"2021122117330007300_CIT0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000368520","article-title":"Discordant clinical course of vitamin-D-hydroxylase (CYP24A1) associated hypercalcemia in two adult brothers with nephrocalcinosis","volume":"40","author":"Jobst-Schwan","year":"2015","journal-title":"Kidney Blood Press Res."},{"key":"2021122117330007300_CIT0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jsbmb.2017.01.006","article-title":"CYP24A1 loss of function: clinical phenotype of monoallelic and biallelic mutations","volume":"173","author":"Carpenter","year":"2017","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"10","key":"2021122117330007300_CIT0010","doi-asserted-by":"crossref","first-page":"E1343","DOI":"10.1210\/jc.2014-4387","article-title":"CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait","volume":"100","author":"Molin","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122117330007300_CIT0011","doi-asserted-by":"crossref","first-page":"E423","DOI":"10.1210\/jc.2011-1935","article-title":"Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy","volume":"97","author":"Tebben","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122117330007300_CIT0012","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-809963-6.00074-2","article-title":"Infantile hypercalcemia and CYP24A1 mutations.","volume-title":"Vitamin D","author":"Schlingmann","year":"2018","edition":"4th ed"},{"issue":"5","key":"2021122117330007300_CIT0013","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/EBC20170053","article-title":"The genetic basis of disease","volume":"62","author":"Jackson","year":"2018","journal-title":"Essays Biochem."},{"issue":"1-2","key":"2021122117330007300_CIT0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jsbmb.2010.03.023","article-title":"Sun exposure questionnaire predicts circulating 25-hydroxyvitamin D concentrations in Caucasian hospital workers in southern Italy","volume":"121","author":"Hanwell","year":"2010","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"7","key":"2021122117330007300_CIT0015","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1210\/jc.2013-4388","article-title":"Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS\/MS involving derivatization with DMEQ-TAD","volume":"99","author":"Kaufmann","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021122117330007300_CIT0016","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/jbmr.3135","article-title":"Improved screening test for idiopathic infantile hypercalcemia confirms residual levels of serum 24,25-(OH)2 D3 in affected patients","volume":"32","author":"Kaufmann","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"6779","key":"2021122117330007300_CIT0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(53)90187-1","article-title":"Idiopathic hypercalcaemia in infants","volume":"265","author":"Lightwood","year":"1953","journal-title":"Lancet"},{"issue":"5","key":"2021122117330007300_CIT0018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocr Rev."},{"issue":"3","key":"2021122117330007300_CIT0019","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1210\/jc.2013-3802","article-title":"A lifetime of hypercalcemia and hypercalciuria, finally explained","volume":"99","author":"Jacobs","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122117330007300_CIT0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00240-016-0923-4","article-title":"A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass","volume":"45","author":"Ferraro","year":"2017","journal-title":"Urolithiasis."},{"issue":"5","key":"2021122117330007300_CIT0021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/qjmed\/hcy265","article-title":"Seasonal hypercalcaemia; consider CYP24A1 mutation","volume":"112","author":"Willows","year":"2019","journal-title":"QJM."},{"issue":"1","key":"2021122117330007300_CIT0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.ajkd.2014.06.037","article-title":"Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations","volume":"65","author":"Figueres","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"39","key":"2021122117330007300_CIT0023","doi-asserted-by":"crossref","first-page":"14467","DOI":"10.1074\/jbc.RA119.010173","article-title":"A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues","volume":"294","author":"Meyer","year":"2019","journal-title":"J Biol Chem."},{"issue":"2","key":"2021122117330007300_CIT0024","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ckj\/sft008","article-title":"Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcaemia and a novel CYP24A1 mutation","volume":"6","author":"Meusburger","year":"2013","journal-title":"Clin Kidney J."},{"issue":"24","key":"2021122117330007300_CIT0025","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1074\/jbc.RA119.008760","article-title":"Targeted genomic deletions identify diverse enhancer functions and generate a kidney-specific, endocrine-deficient Cyp27b1 pseudo-null mouse","volume":"294","author":"Meyer","year":"2019","journal-title":"J Biol Chem."},{"issue":"Pt 2","key":"2021122117330007300_CIT0026","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/000456329803500203","article-title":"Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation","volume":"35","author":"Payne","year":"1998","journal-title":"Ann Clin Biochem."},{"issue":"10","key":"2021122117330007300_CIT0027","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s00198-016-3615-6","article-title":"Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect","volume":"27","author":"O\u2019Keeffe","year":"2016","journal-title":"Osteoporos Int."},{"issue":"4","key":"2021122117330007300_CIT0028","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1159\/000500922","article-title":"Novel CYP24A1 mutation in a young male patient with nephrolithiasis: case report","volume":"44","author":"Jir\u00e1\u010dkov\u00e1","year":"2019","journal-title":"Kidney Blood Press Res."},{"issue":"2","key":"2021122117330007300_CIT0029","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2013.02.3188","article-title":"Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis","volume":"190","author":"Dinour","year":"2013","journal-title":"J Urol."},{"issue":"1","key":"2021122117330007300_CIT0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00467-014-2889-1","article-title":"Maternal and infantile hypercalcemia caused by vitamin-D-hydroxylase mutations and vitamin D intake","volume":"30","author":"Dinour","year":"2015","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"2021122117330007300_CIT0031","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000446663","article-title":"Mutational spectrum of CYP24A1 gene in a cohort of Italian patients with idiopathic infantile hypercalcemia","volume":"133","author":"Gigante","year":"2016","journal-title":"Nephron."},{"issue":"6","key":"2021122117330007300_CIT0032","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MPA.0000000000000577","article-title":"Hypercalcemic pancreatitis triggered by pregnancy with a CYP24A1 mutation","volume":"45","author":"Kwong","year":"2016","journal-title":"Pancreas."},{"issue":"2","key":"2021122117330007300_CIT0033","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1210\/jc.2004-0966","article-title":"CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis","volume":"90","author":"Gupta","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122117330007300_CIT0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-nutr-071812-161203","article-title":"Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs","volume":"33","author":"Jones","year":"2013","journal-title":"Annu Rev Nutr."},{"issue":"8","key":"2021122117330007300_CIT0035","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2006-0710","article-title":"C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status","volume":"91","author":"Singh","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122117330007300_CIT0036","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2016-4048","article-title":"CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations","volume":"102","author":"Hawkes","year":"2017","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa876\/35196254\/dgaa876.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/3\/708\/41832113\/dgaa876.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/3\/708\/41832113\/dgaa876.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T17:49:17Z","timestamp":1640108957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/3\/708\/6010373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,29]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,29]]},"published-print":{"date-parts":[[2021,3,8]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa876","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,29]]}}}